Ipsen : Onivyde approved in 1L against pancreatic cancer
>FDA approval in 1L (vs 2L to date) - Yesterday, Ipsen received notification from the FDA for the approval of Onivyde® in combination with oxaliplatine, fluorouracile and leucovorine (Nalirifox), as a first line (1L) treatment for adult patients with metastatic pancreatic ductal adenocarcinoma. Since 2015, Onivyde® has been approved (also in association with fluorouracile and leucovorine) but following disease progression after gemcitabine-based treatment i.e. in 2L.§...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.